Clinigen Group (CLIN)


CLIN Share PerformanceMore

52 week high890.0 11/05/17
52 week low492.8 16/06/16
52 week change 326.5 (59.10%)
4 week volume6,564,420 02/05/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Clinigen achieves positive Cardioxane CHMP opinion

Clinigen's specialty pharma division has achieved a positive CHMP opinion in Europe to modify the current product infor...

Clinigen achieves positive Cardioxane CHMP opinion

RNS Number: 7353F Clinigen Group plc 22 May 2017 RNS Reach 22 May 2017 Clinigen achieves positive CHMP opinion concerning Cardioxane in Europe Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, announces that its Specialty Pharma (SP) division has achieved a positive CHMP opinion in Europe to mo...

Fund manager's favourite small-cap pharma shares

If you're looking for capital growth, don't bother with big pharma, argues fund manager Paul Mumford. He tells Lee Wild...

Clinigen and TESARO launch European MA programme

Clinigen Group's Idis managed access division and TESARO Inc have partnered to launch a managed access programme in...

Clinigen and TESARO launch European MA Program

RNS Number: 7896E Clinigen Group plc 11 May 2017 RNS Reach 11 May 2017 Clinigen and TESARO partner to initiate European Managed Access Program for niraparib for patients with recurrent ovarian cancer Clinigen Group plc's (AIM: CLIN, 'Clinigen') Idis Managed Access division and TESARO Inc. ( NASDAQ: TSRO) have partnered to launch a Managed Acce...

Director Deals - Clinigen Group (CLIN)

Peter George, Chief Executive Officer, has transferred out 43,000 shares in the company on the 4th May 2017 at a price of ...

Holding(s) in Company

RNS Number: 0516E Clinigen Group plc 03 May 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Clinigen Group PLC 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acquisit...

Clinigen and Onxeo initiate MA programme in Europe

RNS Number: 1822D Clinigen Group plc 25 April 2017 RNS Reach 25 April 2017 Clinigen and Onxeo initiate Managed Access programme for belinostat in Europe for patients with peripheral T-cell lymphoma (PTCL) Clinigen Group plc's (AIM: CLIN, 'Clinigen' or the 'Group') Idis Managed Access ('MA') division and Onxeo S.A (Euronext Paris, Nasdaq Copenhagen: ON...

Fundamental DataMore

P/E ratio73.866
Dividend yield0.455 %

Equity Research (CLIN)

Clinigen Group Plc
Magnolia Petroleum (MAGP.L) 0.14p £2.45m US onshore focused oil and gas exploration and production company, announced the results of an independent Reserves Report.  The Report, which is part of the...
edison investment research
Clinigen Group Plc
Edison Investment Research is terminating coverage on Clinigen Group (CLIN). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be...
edison investment research
Clinigen Group Plc
Clinigen’s H116 trading statement suggests its business is performing to plan, taking into account some revenue deferrals to H2. The integration of Idis and Link, which we expect to boost its...

Latest discussion posts More

  • Re: Share Price

    Maybe it is is down to President Trump trying to remove obama care with his new healthcare bill, voting later today.
  • Share Price

    Can anyone comment on the decline in the share price? Appreciate any commentary.
  • results tomorrow


Users' HoldingsMore

Users who hold Clinigen Group also hold..
RDS 'B'18%

Codes & Symbols